Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer

Abstract New therapeutics and combination regimens have led to marked clinical improvements for the treatment of a subset of colorectal cancer. Immune checkpoint inhibitors have shown clinical efficacy in patients with mismatch-repair–deficient or microsatellite instability–high (MSI-H) metastatic colorectal cancer (mCRC). However, patients with microsatellite-stable (MSS) or low levels of microsatellite instable (MSI-L) colorectal cancer have not benefited from these immune modulators, and the survival outcome remains poor for the majority of patients diagnosed with mCRC. In this article, we describe the discovery of a novel T-cell–dependent bispecific antibody (TDB) targeting tumor-associated antigen LY6G6D, LY6G6D-TDB, for the treatment of colorectal cancer. RNAseq analysis showed that LY6G6D was differentially expressed in colorectal cancer with high prevalence in MSS and MSI-L subsets, whereas LY6G6D expression in normal tissues was limited. IHC confirmed the elevated expression of LY6G6D in primary and metastatic colorectal tumors, whereas minimal or no expression was observed in most normal tissue samples. The optimized LY6G6D-TDB, which targets a membrane-proximal epitope of LY6G6D and binds to CD3 with high affinity, exhibits potent antitumor activity both in vitro and in vivo. In vitro functional assays show that LY6G6D-TDB–mediated T-cell activation and cytotoxicity are conditional and target dependent. In mouse xenograft tumor models, LY6G6D-TDB demonstrates antitumor efficacy as a single agent against established colorectal tumors, and enhanced efficacy can be achieved when LY6G6D-TDB is combined with PD-1 blockade. Our studies provide evidence for the therapeutic potential of LY6G6D-TDB as an effective treatment option for patients with colorectal cancer.

[1]  Vahan B. Indjeian,et al.  Development of an ultra-sensitive human IL-33 biomarker assay for age-related macular degeneration and asthma drug development , 2021, Journal of Translational Medicine.

[2]  K. H. Hoi,et al.  Rapid identification of anti-idiotypic mAbs with high affinity and diverse epitopes by rabbit single B-cell sorting-culture and cloning technology , 2020, PloS one.

[3]  R. Rowntree,et al.  An Anti–CD22-seco-CBI-Dimer Antibody–Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models , 2020, Molecular Cancer Therapeutics.

[4]  Meric A. Ovacik,et al.  Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody. , 2020, JCI insight.

[5]  A. Jemal,et al.  Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[6]  J. Narula,et al.  A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers , 2020, Clinical Cancer Research.

[7]  Z. Stadler,et al.  Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.

[8]  F. Ciardiello,et al.  Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. , 2019, Cancer treatment reviews.

[9]  D. Ellerman Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. , 2019, Methods.

[10]  L. Cerulo,et al.  JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer , 2019, Journal of experimental & clinical cancer research : CR.

[11]  David J. Hermel,et al.  The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer , 2019, Journal of personalized medicine.

[12]  P. Schnier,et al.  High-resolution glycosylation site-engineering method identifies MICA epitope critical for shedding inhibition activity of anti-MICA antibodies , 2018, mAbs.

[13]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Desai,et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.

[15]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[16]  J. Albanell,et al.  Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). , 2017 .

[17]  Thomas D. Wu,et al.  Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing , 2017, Cancer cell.

[18]  Genee Y. Lee,et al.  An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. , 2017, Blood.

[19]  E. Bruford,et al.  Organization, evolution and functions of the human and mouse Ly6/uPAR family genes , 2016, Human Genomics.

[20]  James R. Apgar,et al.  Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer , 2016, Antibodies.

[21]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Diego Ellerman,et al.  Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies , 2015, Science Translational Medicine.

[23]  A. Ebens,et al.  Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. , 2014, Cancer research.

[24]  B. Mumey,et al.  Antigen-antibody interface properties: composition, residue interactions, and features of 53 non-redundant structures. , 2012, Biochimica et biophysica acta.

[25]  P. Kufer,et al.  Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen , 2010, Cancer Immunology, Immunotherapy.

[26]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[27]  Carsten Reinhardt,et al.  Bispecific T-cell engaging antibodies for cancer therapy. , 2009, Cancer research.

[28]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[29]  Begoña Aguado,et al.  Characterization of the five novel Ly‐6 superfamily members encoded in the MHC, and detection of cells expressing their potential ligands , 2006, Protein science : a publication of the Protein Society.

[30]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[31]  R. Campbell,et al.  Transcriptional analysis of a novel cluster of LY-6 family members in the human and mouse major histocompatibility complex: five genes with many splice forms. , 2002, Genomics.

[32]  L. Simmons,et al.  Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. , 2002, Journal of immunological methods.

[33]  J. Wells,et al.  Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. , 1997, Journal of molecular biology.

[34]  L. Presta,et al.  X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. , 1993, Journal of molecular biology.

[35]  Hans Clevers,et al.  Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models , 2017, Cell Death & Differentiation.

[36]  W. Delano The PyMOL Molecular Graphics System , 2002 .